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Highlights 
• The switch to DTG+2NRTIs appeared to be effective with 4% (95% CI 1.6-5.5) probability 
of virological failure at 12 months 
• Previous NRTIs resistance does not affect the efficacy of switching to DTG+2NRTIs 
regimens  
• Time of viral suppression before the switch to DTG+2NRTIs correlates with the risk of 
virological failure 
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Abstract 
The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) 
backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of 
previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of 
virological failure (VF) in patients, under virological control, who switched to dolutegravir 
(DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen 
composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or 
tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-
RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors 
were excluded. The impact of single and combined NRTIs mutations on the probability of VF 
(defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1,000 copies/mL) was 
assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to 
assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the 
analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of 
whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model 
no association was observed between NRTIs mutations and VF. Conversely, the duration of viral 
suppression before switch resulted associated with a lower risk of VF (for 1 month increase, 
adjusted 0.98, 95%CI 0.96-0.99; p=0.024). Previous NRTIs mutations appeared to have no impact 
on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled 
viremia decreased significantly the risk of VF. 
Key words: Dolutegravir; drug resistance; genotypic resistance test; M184V/I; NNRTIs. 
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In the past decades antiretroviral therapy (ART) has dramatically changed the natural history of 
HIV-1 infection by transforming an invariably fatal disease into a chronic one [1]. The advent of a 
new class of antiretroviral, integrase inhibitors (INIs), has provided new effective and well tolerated 
ART options both in naïve [2-5] and experienced patients [6-7]. Simplification strategies based on 
INIs are increasingly used in clinical practice with the aim to improve the tolerability and to avoid 
potential long-term metabolic untoward effects of other antiretrovirals, i.e. boosted protease 
inhibitors (PIs) [8-10]. In the first simplification studies assessing the efficacy of INIs 
(SWITCHMRK and SPIRAL) the switch to raltegravir (RAL) was compared with maintaining PIs-
based regimens. The inclusion criteria of both studies allowed the enrolment of patients with 
previous virological failure (VF) [11, 12]. In the SWITCHMRK, RAL based regimens failed to 
meet non inferiority when compared to boosted lopinavir containing regimens, with a not negligible 
percentage of patients developing resistance to RAL documented by the genotypic resistance test 
(GRT) [11]. Conversely, the SPIRAL study established the non-inferiority of RAL to PIs-
containing regimens [12]. When compared to first generation INIs (i.e. RAL and elvitegravir), 
dolutegravir (DTG) presents a higher genetic barrier [13]. Nevertheless, due to the high rate of VF 
observed in the SWITCHMRK, patients with previous VF, with documented resistance to one of 
the investigated ART components, were subsequently excluded from the DTG switch studies [6, 7, 
11]. Therefore, only data derived from observational studies are available regarding the potential 
impact of previous reverse transcriptase (RT) mutations on the virological efficacy of DTG triple 
therapy [14-16]. 
The aim of the present study was to assess the impact of previous drug resistance to nucleoside 
reverse transcriptase inhibitors (NRTIs) on the probability of VF in HIV-1 positive drug-
experienced patients, with an undetectable HIV-RNA (<50cp/mL) and at least one previous GRT, 
who switched to a dolutegravir (DTG)+2 NRTIs regimen. 
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We performed a retrospective observational study using the Antiviral Response Cohort Analysis 
(ARCA) database (https://www.dbarca.net/), which prospectively collects data on HIV resistance 
and ART; at present, data from >41,000 patients in Italy are available [17]. The ARCA database 
was queried to retrieve the data of HIV-1-positive patients with (i) age ≥18 years, (ii) HIV-RNA 
≤50 copies/mL at the time of the switch, (iii) subsequently switching to DTG + 
tenofovir/emtricitabine (TDF/FTC) or tenofovir alafenamide (TAF)/FTC or abacavir/lamivudine 
(ABC/3TC) for any reason, (iv) with at least 1 previous GRT, (v) with at least 1 virological and 
clinical follow-up after switching to DTG + 2NRTIs. Patients with a previous VF to INIs-
containing regimens were excluded from the analysis.  
The occurrence of any NRTIs mutation was determined using historical GRT; mutations were 
assessed by the Stanford list Version 8.7 update 2018-10-19 [18]. The mutations considered in the 
analysis were M184V/I, K65R, Q151M, the T69 insertion, the thymidine analogues mutations 
(TAM)-1 (M41L, L210W, and T215Y), TAM-2 (D67N, K70R, T215F, and K219Q/E) and 
cumulative TAM; moreover, any of these mutations in whatever previous GRT was considered as 
positive. 
The primary end-point was to assess the impact of single and combined RT mutations in the 
historical GRT on the probability of VF (defined as 2 consecutive HIV-RNA > 50 copies/mL or one 
HIV-RNA >1,000 copies/mL) after the switch to an antiretroviral regimen composed by 
DTG+TDF/FTC or TAF/FTC or ABC/3TC in patients with an HIV-RNA <50 copies/mL at the 
time of switching. 
Standard survival analyses with Kaplan-Meier curves were used to analyse the probability of time 
to VF. Patients were followed from the switch to DTG+2NRTIs to the study outcomes, last 
available follow-up, or December 5, 2018, whichever occurred first.  
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Patients switching for any reason to an ART other than DTG+2NRTIs or loss to follow up were 
censored in the survival analysis.  
To assess the predictors of VF a univariate and multivariable Cox proportional hazard model was 
built. The following variables were considered in the final model: age, gender, transmission route, 
concomitant use of ABC or TDF/TAF backbone, HIV-RNA zenit, CD4 cell counts nadir, number 
of previous antiretroviral lines, years on combined antiretroviral treatment, time of pre-switch viral 
suppression, the presence of K65R, M184V/I or 3 or more TAMs. 
All analyses were performed using the SPSS v.22.0 software package. P values of less than .05 
were considered significant. 
The study was performed in accordance with the ethical standards of the 1964 Declaration of 
Helsinki and later amendments. All patients signed an informed consent for use of their clinical and 
laboratory data in aggregated and anonymous form. Access to the database and data analyses were 
regulated by local institutional ethics committees and by Italian and European privacy legislation. 
Five hundred and eighty-eight patients were included in the analysis, 423 (71.9%) of whom were 
males, with a median age of 51 years [Inter quartile range (IQR) 44-56] and 165 (28.1%) were 
receiving TDF or TAF/FTC. Patient’s baseline characteristics at the time of the switch are reported 
in Table 1. Overall, the median number of previous regimens was 3 (IQR 1-6) and the median time 
of viral suppression before the switch was 31 months (IQR 12-78). One hundred and forty-eight 
patients (25.2%) presented at least one NRTIs mutations in their historical GRT, 102 (17.3) had the 
M184V/I mutation and 77 (13.1%) 3 or more TAMs. 
The median time of observation was 12 months (IQR 6-19). During this time, 259 (44%) patients 
discontinued DTG+2NRTIs for any reason (20.8% were for toxicity, 13.1% for simplification, 
15.9% for other reasons, 2.3% for VF and not reported for 47.9% of patients). Cumulative VF 
occurred in 19 (3.2%) subjects. At 12 months the overall probability of experiencing a VF was 4% 
[95% Confidence Interval (95% CI 1.6-5.5)]. 
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According to the historical GRT, the probability of having a VF at 12 months in patients with or 
without any NRTIs mutation was 5% (95% CI 0.6-10.2) and 3% (95% CI 1-4.9) (p=0.635), 
respectively. No difference was observed at 12 months in the rate of VF in patients harbouring or 
not in their historical GRT the M184V/I mutation [7% (95% CI 0.9-13.8) vs 3% (95% CI 0.9-4.5); 
p=0.420] and 3 or more TAMs [5% (95% CI 0-12) vs 3% (95% CI 1.3-5.4); p=0.871] . Moreover, 
no difference in the rate of VF failure was observed when combining M184V/I and K65R mutations 
(p=0.061). 
In the multivariable Cox proportional hazard model, after correcting for age, gender, risk factors, 
immune-virological status and years on ART, no significant association was observed between 
NRTIs mutations and VF. Conversely, the time of viral suppression before the switch resulted 
associated with a lower risk of VF [for 1 month increase, adjusted 0.98 (95% CI 0.96-0.99); 
p=0.024] (Table 2). 
Our study highlights the virological efficacy of DTG+2NRTIs combination therapy with only 3.2% 
of patients who discontinued the regimen due to VF during the time of observation. This finding is 
in line with the virological efficacy of DTG based regimens reported in observational studies with a 
mixed population of patients harbouring or not resistance to NRTIs [15, 16, 19].  
In our study we observed no impact of previous NRTIs resistance according to the historical GRT 
on the risk of VF of ART composed by DTG+2 NRTIs. This finding is interesting because no 
information is available from randomized clinical trial due to the exclusion of patients with previous 
NRTIs mutations [6, 7]. Nevertheless, a recent large observational study conducted in several 
European countries confirmed the absence of the impact of M184V/I on the virological efficacy of 
ABC/3TC/DTG regimen in switch strategy [15]. Furthermore, the DAWNING study showed that, 
in patients failing their first antiretroviral regimen, DTG was superior to boosted lopinavir in 
obtaining virological suppression at 48 weeks [20]. Very recently, two Phase 3 
TAF/FTC/bictegravir (BIC) switch studies (studies 1878 and 1844) demonstrated a high rate of 
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virological suppression at week 48 in the overall population and in subjects with pre-existing 
resistance, including M184V/I [21]. Taken together these results support the implementation of 
DTG or BIC-based ART in resource limited setting also in patients with previous VF to NRTIs 
containing regimens [22, 23]. 
In our study no association was observed between previous PIs exposure and the risk of VF, thereby 
supporting the findings reported by Chen et al. who evaluated patients switching from boosted PIs 
to DTG with or without previous NRTIs mutations [16]. These results highlight the high genetic 
barrier of DTG [13] and they might support the use of DTG-based ART as alternative regimens in 
simplification strategies from boosted PIs in patients with previous NRTIs resistance [6, 10]. 
Nevertheless, in our study we observed a high rate of DTG+2NRTIs treatment interruption due to 
any causes. Consequently, if on one hand we can infer about the virological efficacy of the DTG-
containing regimen, on the other hand the tolerability of such regimen might be questioned, 
possibly due to central nervous system side effects and weight gain [24, 25]. 
In our study, we found an association between the time of pre-switch viral suppression and the risk 
of VF. The importance of the duration of viral suppression before the switch was highlighted by the 
different results of the first two switch trial of RAL, SWITCHMRK and SPIRAL [11, 12]. In the 
SWITCHMRK, a pre-switch time of viral suppression of more than 3 months was allowed, with 
approximately 18% of patients with less than one year of boosted lopinavir exposure before 
randomization, and the non inferiority of RAL-based regimens was not met [11]. On the contrary, in 
the SPIRAL study demonstrating the non inferiority of RAL, patients had a longer median time of 
viral suppression before the switch [67 months (IQR 59–73)] [12]. Moreover, in the study by 
Olearo et al, in which patients had a longer viral suppression than in our study before switching to 
ABC/3TC/DTG (134 months and 83.5 months in those with and without M184V/I vs 31 months, 
respectively), no impact of the time of viral suppression on VF was observed [15]. 
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Our study has several limitations. First, the observational nature of the study could have affected the 
results due to missing or incomplete data. In particular, an intrinsic limitation in the dataset regards 
the reasons of DTG+2NRTIs discontinuation, thus challenging the inference about tolerability of 
such ART. Second, the high discontinuation rate and the median time of observation of only 12 
months did not allow to assess the long term impact of NRTIs mutations. Third, a very few VFs 
were observed despite our conservative definition of VF, although in line with the rate reported in 
previous works [15, 16]. Finally, when considering the K65R mutation, a type 2 error cannot be 
excluded due to the low number of cases and consequently our findings should not be generalized to 
such patients.  
According to our findings, the risk of VF after switching to DTG+2NRTIs appears to be low. 
Previous NRTIs mutations seem to have no impact on the risk of VF in patients under virological 
control on ART regimens based on DTG+2NRTIs. Moreover, a longer time of virological 
suppression before the switch resulted associated to a reduced risk of VF. Thus, caution should be 
warranted when considering the switch to DTG+2NRTIs in patients with a short time of viral 
suppression. 
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Table 1. Characteristic of the study population at time of the switch. 
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Patients characteristics Total n=588 
Gender, n (%)   
    Male  423 (71.9) 
    Female 165 (28.1) 
Median Age (yrs), (IQR) 51 (44-56) 
Epidemiology, n (%)   
    Sexual Risk 327 (55.6) 
    IDUs 109 (18.5) 
    Other 9 (1.6) 
    Unknown 143 (24.3) 
Years on ART, median (IQR) 8 (4-17) 
Number of previous ART regimens, median (IQR) 3 (1-6) 
Months of viral suppression before switch, median (IQR) 31 (12-78) 
CD4 cells nadir < 200 cell/µL, n (%) 302 (51.4) 
HIV-RNA zenit cp/mL Log, median (IQR) 5.0 (4.4-5.6) 
Previous AIDS events, n (%) 56 (9.5%) 
Backbone, n (%)   
    ABC  423 (71.9) 
    TDF/TAF  165 (28.1) 
Switch from a PIs containing regimen, n (%) 323 (54.9) 
HCV, n (%)   
    Positive 145 (24.7) 
    Negative 234 (39.8) 
    Unknown 209 (35.5) 
HBV, n (%)   
    Positive 82 (14) 
    Negative 307 (52.2) 
    Unknown 199 (33.8) 
Previous NRTIs resistance, n (%)   
    M184V/I 102 (17.3) 
    K65R  6 (1.0) 
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List of abbreviations:  n= number, yrs= years, IDUs= intravenous drug users, ABC= abacavir, 
TDF= tenofovir disoproxil fumarate, TAF= tenofovir alafenamide, PIs= protease inhibitors, 
NRTIs= nucleoside reverse transcriptase inhibitors, TAMs= thymidine analogues mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    3 or more TAMs 77 (13.1) 
    Any NRTIs mutation 148 (25.2) 
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Table 2. Uni and multivariable analysis of factors associated with VF after switching to DTG + 2 NRTIs. 
 
List of abbreviations: HR= Hazard Ratio, aHR= adjusted Hazard Ratio, CI= Confidence Interval, 
IDUs= intravenous drug users, ABC= abacavir, TDF= tenofovir disoproxil fumarate, TAF= 
tenofovir alafenamide, PIs= protease inhibitors, TAMs= thymidine analogues mutations. 
 
 
 
 
  HR 95% CI p   aHR 95% CI p 
Male vs Female 1.53 0.60-3.90 0.373   2.49 0.90-6.89 0.079 
Age (per 1 year more) 0.99 0.95-1.04 0.798   0.99 0.94-1.05 0.767 
IDUs vs Sexual Risk 2.75 1.03-7.30 0.043   2.65 0.73-9.57 0.137 
Unknown vs Sexual Risk 1.09 0.29-4.11 0.900   1.36 0.32-5.88 0.685 
ABC vs TDF/TAF 0.65 0.26-1.64 0.367   1.06 0.35-3.23 0.914 
Zenit RNA (per 1 Log increase) 1.63 0.95-2.78 0.077   1.81 0.92-3.58 0.085 
CD4 nadir <200 vs >200/mmc 0.84 0.34-2.06 0.699   0.56 0.20-1.55 0.265 
Number of previous lines (per 1 more) 1.05 0.95-1.15 0.333   0.98 0.82-1.17 0.806 
Years on cART (per 1 year more) 1.01 0.95-1.08 0.722   1.03 0.93-1.15 0.559 
Time of viral suppression (per 1 month 
increase) 
0.98 0.96-0.99 0.019   0.98 0.96-0.99 0.029 
Switch from a PIs containing regimen 0.55 0.22-1.41 0.214  0.42 0.15-1.18 0.101 
K65R mutation presence 5.14 0.68-
38.90 
0.112   3.23 0.27-38.40 0.352 
3 or more TAMs presence 1.11 0.32-3.82 0.871   2.01 0.30-13.41 0.470 
M184V/I mutation presence 1.52 0.55-4.21 0.424   0.99 0.19-5.21 0.986 
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